FDA tells Pharma not to fret about proving PCSK9 inhibitors reduce heart attacks

Eric Palmer FiercePharma News

Pennsylvania Moves Closer To Adopting Biosimilar Legislation

esilverman Biotechs fighting to thwart biosimilar substitution have just moved closer to achieving their goal in one big state. A Pennsylvania senate committee has approved ...

BioMarin’s rare disease drug gets so-so FDA review

Damian Garde BioMarin's drug for a rare enzyme deficiency resulted in a "modest" improvement for patients, according to an FDA staff review, possibly lowering expectations ...

J&J reportedly settles 7,500 hip-replacement lawsuits for $4B

Tracy Staton Johnson & Johnson has reportedly wrapped up thousands of lawsuits over faulty hip-replacement products with a hefty $ 4 billion settlement. FiercePharma News

Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

barbara.lempert Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly First-in-class antipsychotic therapy for Schizophrenia and Bipolar Disorders London, UK, 13 ...

Sanofi gets mixed FDA blessing for MS drug Lemtrada

Damian Garde After a scathing staff review, Sanofi walked away from an FDA panel with mixed messages on its long-delayed multiple sclerosis drug, as agency advisers said the injection ...

CFR chief angles for meeting with Adcock after top investor nixes $1.3B deal

Tracy Staton Chile's CFR Pharmaceuticals is threatening to pull its $ 1.3 billion bid for South African drugmaker Adcock Ingram if the latter's biggest shareholder doesn't ...

Actavis to shed 310 jobs in shutdown of NC plant

Tracy Staton Actavis says it's planning to close a plant in North Carolina–and cut 310 jobs in the process. FiercePharma News

Former FDA Commishs To White House: Limit Antibiotics In Livestock

esilverman A pair of former FDA commissioners has written a letter to the White House Office of Management and Budget to urge the Obama administration to end the use of antibiotics ...

Liquidia spins out new biotech with $25M A round

John Carroll Liquidia Technologies has spun out a new biotech company in Research Triangle Park, NC, which boasts an early-stage ophthalmology program and $ 25 million in venture backing ...

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

Tracy Staton When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there ...

Peregrine Shares Bavituximab Data

mia.burns Data Presentation at Society for Immunotherapy of Cancer Annual Meeting Supports Potential of Peregrine Pharmaceuticals’ Novel Immunotherapy Bavituximab in Combination ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS